Personalized Medicine – News and Features

A new study from Charité University reveals that the biomarker Ki67 can predict if inflammatory bowel disease patients will respond to vedolizumab. Machine learning identified Ki67 levels as a marker for treatment resistance.

Using CRISPR-Cas13, NYU researchers reveal that noncoding RNAs, previously deemed “junk,” are crucial for cell function and development. Their findings, published in Cell, identify nearly 800 essential noncoding RNAs.

A team created UAB36, a polygenic score based on 36 genes linked to drug resistance, showing promise in predicting cancer treatment outcomes.UAB36 outperformed other scores, offering a potential tool for tailoring personalized cancer therapies.

Researchers discovered that gene deserts, non-coding DNA regions, regulate heart and embryo development through enhancer elements controlling key genes. This insight into gene deserts’ role in heart health could aid genetic diagnostics.

A study reveals that triple-negative breast cancer cells prompt immune cells to form "molecular bridges," leading to immune suppression. An antibody treatment blocking these bridges shows promise in enhancing the immune response.

A study from the Buck Institute reveals that threonine, an essential amino acid, could extend lifespan in both fruit flies and humans. By utilizing machine learning and systems biology, researchers linked key metabolites between species.

Researchers trained and validated an AI model based on MRI scans from more than 700 prostate cancer patients. The model was able to identify and demarcate the edges of 85% of the most radiologically aggressive prostate lesions.

At this year’s HUPO annual meeting, the 24th version of the Human Protein Atlas has launched. We interviewed the HPA's program director, Professor Mathias Uhlén, to learn about its new features.

A study has found that IBS patients with genetic defects in carbohydrate digestion respond better to a carbohydrate-reduced diet. This research suggests that genetic markers can predict dietary treatment efficacy.

Technology Networks asked a selection of start-up companies at ELRIG Drug Discovery how their technology addresses key limitations in traditional disease models.